Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Doxapram.
- Who it may be relevant to
- Registry conditions: COPD, Mechanical Ventilation, Weaning From Mechanical Ventilation. Basic parameters: 20 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Influence of Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial: a Prospective Observational Study
Overview
Researchers aim to evaluate the impact of doxapram administration on diaphragmatic excursion in chronic obstructive pulmonary disease (COPD) patients undergoing spontaneous breathing trial
Detailed description
doxapram will be administered intravenously (IV) during spontaneous breathing trial. diaphragmatic excursion will be evaluated by an expert in respiratory muscle ultrasound
Interventions
- Drug Doxapram
Doxapram will be given as 1.5 mg/kg will be given 10 minutes after the initiation of SBT
Primary outcome measures
- • Diaphragmatic excursion in mm [Time frame: before and 10 minutes after doxappram]
Secondary outcome measures (2)
- Arterial blood gases [Time frame: before and 10 minutes after doxapram]
- Respiratory rate [Time frame: before and 10 minutes after doxapram]
Eligibility criteria
Inclusion criteria
- Patients with moderate to severe chronic obstructive pulmonary disease undergoing spontaneous breathing trial
Exclusion criteria
- Refusal Allergy to doxapram neuromuscular disorders inability to evaluate the diaphragm
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Egypt · 1 center
- Cairo University — Cairo
Publications
- Helmy MA, Magdy Milad L, Osman SH, Ali MA, Hasanin A. Diaphragmatic excursion: A possible key player for predicting successful weaning in patients with severe COVID-19. Anaesth Crit Care Pain Med. 2021 Jun;40(3):100875. doi: 10.1016/j.accpm.2021.100875. Epub 2021 Apr 30. No abstract available. PMID 33940248
- Pourriat JL, Baud M, Lamberto C, Fosse JP, Cupa M. Effects of doxapram on hypercapnic response during weaning from mechanical ventilation in COPD patients. Chest. 1992 Jun;101(6):1639-43. doi: 10.1378/chest.101.6.1639. PMID 1600786
- Oikawa S, Nomura H, Nishio M, Nagata R, Hata T. Doxapram hydrochloride aggravates adrenaline-induced arrhythmias accompanied by bidirectional ventricular tachycardia. ISRN Cardiol. 2014 Jan 9;2014:212045. doi: 10.1155/2014/212045. eCollection 2014. PMID 24527224
- Rutka M, Palac M, Linek P. Diaphragmatic Mobility Loss in Subjects With Moderate to Very Severe COPD May Improve After In-Patient Pulmonary Rehabilitation. Respir Care. 2021 Feb;66(2):354. doi: 10.4187/respcare.08687. No abstract available. PMID 33514664
- Scheibe N, Sosnowski N, Pinkhasik A, Vonderbank S, Bastian A. Sonographic evaluation of diaphragmatic dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis. 2015 Sep 11;10:1925-30. doi: 10.2147/COPD.S85659. eCollection 2015. PMID 26392767
Identifiers
NCT: NCT07022704 · Doxapram in COPD